Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239694 | PMC |
| http://dx.doi.org/10.1002/hon.2872 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study on the Technical Parameters for Estimating HIV-1 Incidence by Using a Recombinant Antigen-based Capture Enzyme Immunoassay - China.
China CDC Wkly
November 2024
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Introduction: A novel recombinant antigen-based capture enzyme immunoassay (RAg-CEIA) was optimized and used to determine technical parameters for estimating human immunodeficiency virus type 1 (HIV-1) incidence in China.
Methods: We employed orthogonal experimental design to optimize RAg-CEIA by adjusting raw material dilution ratios. The assay was used to measure normalized optical density (ODn) values in 171 longitudinal plasma specimens from 51 HIV-1 seroconverting individuals, plotted against estimated days post-seroconversion.
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.
Wellcome Open Res
December 2024
KEMRI-Wellcome Trust Research Programme, KILIFI, Coast, 230-80108, Kenya.
Background: Given the low levels of coronavirus disease 2019 (COVID-19) vaccine coverage in sub-Saharan Africa (sSA), despite high levels of natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) exposures, strategies for extending the breadth and longevity of naturally acquired immunity are warranted. Designing such strategies will require a good understanding of naturally acquired immunity.
Methods: We measured whole-spike immunoglobulin G (IgG) and spike-receptor binding domain (RBD) total immunoglobulins (Igs) on 585 plasma samples collected longitudinally over five successive time points within six months of COVID-19 diagnosis in 309 COVID-19 patients.
Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity.
Vaccine
January 2025
Center of Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Article Synopsis
- Epidemiological studies show that factors like pre-vaccination immune status, age, gender, and vaccination history affect how people respond to influenza vaccines, but results vary across different studies.* -
- A new Bayesian model was created to analyze the relationships between these host factors and antibody responses after vaccination, revealing that pre-vaccination antibody levels and vaccination history significantly affect post-vaccine antibody dynamics.* -
- The findings suggest that individuals who have been vaccinated less frequently and have lower pre-vaccination antibody levels experience longer durations of effective protection (seroprotection) from the vaccine, with notable differences observed in antibody response to different influenza subtypes.*
Influenza virus infection and aerosol shedding kinetics in a controlled human infection model.
J Virol
December 2024
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.
Unlabelled: Establishing effective mitigation strategies to reduce the spread of influenza virus requires an improved understanding of the mechanisms of transmission. We evaluated the use of a controlled human infection model using an H3N2 seasonal influenza virus to study critical aspects of transmission, including symptom progression and the dynamics of virus shedding. Eight volunteers were challenged with influenza A/Perth/16/2009 (H3N2) virus between July and September 2022 at Emory University Hospital.
View Article and Find Full Text PDFHydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren's syndrome.
Hum Vaccin Immunother
December 2024
The present study aimed at investigating whether the hydroxychloroquine (HCQ) treatment would impact the neutralizing antibody production, viremia levels and the kinetics of serum soluble mediators upon planned 17DD-Yellow Fever (YF) primovaccination (Bio-Manguinhos-FIOCRUZ) of primary Sjögren's syndrome (pSS). A total of 34 pSS patients and 23 healthy controls (HC) were enrolled. The pSS group was further categorized according to the use of HCQ (HCQ and Non-HCQ).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!